Eitan Amir1, Orit Freedman, Lindsay Carlsson, George Dranitsaris, George Tomlinson, Andreas Laupacis, Ian F Tannock, Mark Clemons. 1. *Division of Medical Oncology and Hematology, University of Toronto and Princess Margaret Hospital ‡Ambulatory Care, Princess Margaret Hospital §Toronto General Research Institute, University of Toronto and University Health Network ∥Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto †Department of Medical Oncology, R.S. McLaughlin Durham Regional Cancer Centre, Oshawa ¶Division of Medical Oncology, University of Ottawa and The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.
Abstract
OBJECTIVES: Despite substantial variability in individual risk of skeletal complications, patients with metastatic bone disease are treated with bisphosphonates at the same dose and dosing interval. This study assessed the feasibility of conducting a randomized trial of less frequent bisphosphonate administration in women with breast cancer and low-risk bone metastases. METHODS: A randomized feasibility study was conducted. Patients receiving intravenous bisphosphonates for ≥3 months and with low-risk baseline serum C-telopeptide (CTx) levels (<600 ng/L) were assigned to pamidronate 90 mg intravenously every 3 to 4 weeks (control) or every 12 weeks (de-escalated). CTx, bone alkaline phosphatase, and pain scores (Brief Pain Inventory and Functional Assessment of Cancer Therapy-Bone Pain) were collected every 12 weeks for 48 weeks. RESULTS:Fifty-four patients were approached, 44 consented, and 38 were randomized. Median age was 55 (range, 29 to 77) and median baseline CTx was 163 ng/L (range, 10 to 526). Fourteen control group participants (73.7%) and 13 de-escalated group participants (68.4%) maintained CTx in the low-risk range (P=0.64). All patients changing to higher-risk range had progressive extraskeletal disease. Compared with the control group, there was a time-dependent increase in CTx in the de-escalated group. There were no significant differences in bone alkaline phosphatase, Brief Pain Inventory, or Functional Assessment of Cancer Therapy-Bone Pain. CONCLUSIONS: It is feasible to conduct randomized trials of de-escalated pamidronate in low-risk women treated with ≥3 months of priorbisphosphonate therapy. De-escalated scheduling satisfied our predefined definition of noninferiority compared with 3- to 4-weekly treatment. Larger trials should assess whether increasing CTx levels with de-escalated therapy lead to higher rates of skeletal complications.
RCT Entities:
OBJECTIVES: Despite substantial variability in individual risk of skeletal complications, patients with metastatic bone disease are treated with bisphosphonates at the same dose and dosing interval. This study assessed the feasibility of conducting a randomized trial of less frequent bisphosphonate administration in women with breast cancer and low-risk bone metastases. METHODS: A randomized feasibility study was conducted. Patients receiving intravenous bisphosphonates for ≥3 months and with low-risk baseline serum C-telopeptide (CTx) levels (<600 ng/L) were assigned to pamidronate 90 mg intravenously every 3 to 4 weeks (control) or every 12 weeks (de-escalated). CTx, bone alkaline phosphatase, and pain scores (Brief Pain Inventory and Functional Assessment of Cancer Therapy-Bone Pain) were collected every 12 weeks for 48 weeks. RESULTS: Fifty-four patients were approached, 44 consented, and 38 were randomized. Median age was 55 (range, 29 to 77) and median baseline CTx was 163 ng/L (range, 10 to 526). Fourteen control group participants (73.7%) and 13 de-escalated group participants (68.4%) maintained CTx in the low-risk range (P=0.64). All patients changing to higher-risk range had progressive extraskeletal disease. Compared with the control group, there was a time-dependent increase in CTx in the de-escalated group. There were no significant differences in bone alkaline phosphatase, Brief Pain Inventory, or Functional Assessment of Cancer Therapy-Bone Pain. CONCLUSIONS: It is feasible to conduct randomized trials of de-escalated pamidronate in low-risk women treated with ≥3 months of prior bisphosphonate therapy. De-escalated scheduling satisfied our predefined definition of noninferiority compared with 3- to 4-weekly treatment. Larger trials should assess whether increasing CTx levels with de-escalated therapy lead to higher rates of skeletal complications.
Authors: Brent O'Carrigan; Matthew Hf Wong; Melina L Willson; Martin R Stockler; Nick Pavlakis; Annabel Goodwin Journal: Cochrane Database Syst Rev Date: 2017-10-30
Authors: Mashari Alzahrani; Carol Stober; Michelle Liu; Arif Awan; Terry L Ng; Gregory Pond; Bader Alshamsan; Lisa Vandermeer; Mark Clemons Journal: Support Care Cancer Date: 2022-01-21 Impact factor: 3.603
Authors: Sharon McGee; Mashari AlZahrani; Carol Stober; Terry L Ng; Katherine Cole; Gail Larocque; Arif Awan; Sandeep Sehdev; John Hilton; Lisa Vandermeer; Brian Hutton; Gregory Pond; Deanna Saunders; Mark Clemons Journal: J Bone Oncol Date: 2021-02-19 Impact factor: 4.072
Authors: Christina L Addison; Nathaniel Bouganim; John Hilton; Lisa Vandermeer; Susan Dent; Eitan Amir; Sean Hopkins; Iryna Kuchuk; Roanne Segal; Xinni Song; Stan Gertler; Sasha Mazzarello; George Dranitsaris; Daylily Ooi; Gregory Pond; Mark Clemons Journal: Breast Cancer Res Treat Date: 2014-03-18 Impact factor: 4.872
Authors: Christina L Addison; Gregory R Pond; Huijun Zhao; Sasha Mazzarello; Lisa Vandermeer; Robyn Goldstein; Eitan Amir; Mark Clemons Journal: Springerplus Date: 2014-10-01
Authors: Brian Hutton; Patricia Morretto; Urban Emmenegger; Sasha Mazzarello; Iryna Kuchuk; Christina L Addison; Freya Crawley; Christine Canil; Shawn Malone; Scott Berry; Dean Fergusson; Mark Clemons Journal: J Bone Oncol Date: 2013-06-21 Impact factor: 4.072
Authors: Brian Hutton; Christina Addison; Sasha Mazzarello; Anil A Joy; Nathaniel Bouganim; Dean Fergusson; Mark Clemons Journal: J Bone Oncol Date: 2013-04-15 Impact factor: 4.072
Authors: Brian Hutton; Christina L Addison; Kaitryn Campbell; Dean Fergusson; Sasha Mazarello; Mark Clemons Journal: J Bone Oncol Date: 2013-05-15 Impact factor: 4.072